(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 146.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Absci's revenue in 2025 is $2,815,000.On average, 11 Wall Street analysts forecast ABSI's revenue for 2025 to be $754,865,086, with the lowest ABSI revenue forecast at $397,883,071, and the highest ABSI revenue forecast at $2,309,105,230. On average, 10 Wall Street analysts forecast ABSI's revenue for 2026 to be $4,059,580,222, with the lowest ABSI revenue forecast at $442,092,301, and the highest ABSI revenue forecast at $12,157,538,281.
In 2027, ABSI is forecast to generate $6,134,105,864 in revenue, with the lowest revenue forecast at $442,092,301 and the highest revenue forecast at $16,044,642,358.